北京生物医学工程

国产生物可吸收冠状动脉支架的研究现状

Research status of domestic bioabsorbable coronary artery stents

作者：李崇崇王硕万辰杰王春仁

单位：中国食品药品检定研究院（北京 102629）

分类号：R318.08

出版年·卷·期（页码）：2021·40·1（95-100）

摘要：

心血管介入治疗技术是治疗心血管疾病的重要手段，永久金属支架虽然可以为冠脉狭窄提供支撑，但其在血管内长期存留可引起血管的慢性损伤，后期可造成血管中层萎缩、动脉瘤形成以及反应性内膜增生，最终导致血管再狭窄。随着科学技术的发展和实验的探索，生物可吸收支架正在逐步替代金属永久支架，成为冠状动脉介入治疗发展的新方向。国产冠脉支架的发展经历了模仿、改进、创新的漫长历程，目前新型的生物可吸收冠状动脉支架已经取得了可喜的阶段性研究成果。本文综述了几种国产新型生物可吸收支架的发展情况，归纳其各自的特点和临床试验结果，分析了当前的问题，并对未来的发展做了展望。

Cardiovascular interventional therapy is an important means to treat cardiovascular diseases. Although permanent metal stent can provide support for coronary artery stenosis, its long-term retention in the vessel can cause chronic vascular damage, which can cause vascular medial atrophy, aneurysm formation and reactive intimal hyperplasia, eventually leading to vascular restenosis. With the development of technology and experimental exploration, bioabsorbable stents are gradually replacing metal permanent stents and become a new direction of coronary intervention. The development of domestic coronary stents has experienced a long process of imitation, improvement and innovation. At present, the new bioabsorbable coronary stents have achieved gratifying results. This paper reviews the development of several new domestic bioabsorbable stents, summarizes their respective characteristics and clinical trials, analyzes the current problems, and prospects the future development.

参考文献：

[1] 陈灏珠,林果维,王吉耀,等.实用内科学 [M]. 14版.上海:复旦大学出版社，2014：1466-1467．

Chen HZ, Lin GW, Wang JY, et al. Practical of internal medicine [M]. 14th ed.Shanghai:Fudan University Press,2014:1466-1467．

[2] 陶波,蒋学俊,方钊,等.冠状动脉生物可降解支架的研究现状[J].中国心血管病研究,2016,14(4):289-292.

Tao B, Jiang XJ, Fang Z, et al.The research of biodegradable coronary artery stents[J].

Chinese Journal of Cardiovascular Research,2016,14(4):289-292.

[3] 唐熠达,陈纪林.冠状动脉全降解支架的临床研究进展及展望[J].中国循环杂志,2016 ,31(5):417-419.

[4] 李家睿,冯邦哲,荆小马.介入治疗界的新星——生物可吸收支架[J].国际心血管病杂志,2018,45(3):136-138.

[5] 沈雳,葛均波.生物可吸收支架的利弊之争[J].实用医院临床杂志,2017, 14(1):1-5.

Shen L, Ge JB. Advantages and disadvantages of bioresorbabel scaffold[J].Clinical Journal of Practical Hospital,2017, 14(1):1-5.

[6] 姜凯迪,王春仁,刘丽,等.基于聚乳酸及其共聚物的生物可吸收支架研究进展[J].中国医疗器械信息,2019,25（1）：42-45.

Jang KD, Wang CR, Liu L, et al.Current status and future direction of polymeric biodegradable vascular scaffolds[J].China Medical Device Information,2019, ,25（1）： 42-45.

[7] 胡枝敏，凌望，吴美平. 支架植入后抑制平滑肌细胞过度增殖的研究进展[J].中国医药导报,2020, 17（7）：33-36.

Hu ZM，Ling W，Wu MP. Research progress on inhibiting excessive proliferation of smooth muscle cells after stent implantation[J]. China Medical Herald,2020, 17（7）：33-36.

[8] 郭振,尉海涛,刘全,等.可降解支架与金属药物洗脱支架对冠状动脉狭窄病变PCI术后安全性的影响[J].中国老年学杂志,2018，38(4):780-782.

[9] 高立建,陈纪林.生物可降解支架的临床应用进展[J].中国循环杂志, 2017,32(3):215-216.

[10] 杨承志,乔树宾.生物可降解冠状动脉支架研究进展[J].中国循环杂志, 2015,30(12):1228-1230.

[11] 杨广鑫,栾景源.生物可降解金属血管支架研究进展[J].中国微创外科杂志, 2018,18(8):753-760.

[12] Kerkmeijer LS, Tenekecioglu E, Wykrzykowska JJ．Stent thrombosis in patients with drug-eluting stents and bioresorbable vascular scaffolds: The feared complication[J]. Polish Archives of Internal Medicine-Polskie, 2018,128(1):943-950.

[13] Yamaji K, Ueki Y, Souteyrand G, et al. Mechanisms of very late bioresorbable scaffold thrombosis: The INVEST registry[J]. Journal of the American College of Cardiology, 2017,70(19): 2330-2344.

[14] Chevalier B, Cequier A, Dudek D, et al. Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB Ⅱ Trial )[J]. Eurointervention, 2018,13(13):1561-1564.

[15] Kereiakes DJ, Ellis SG, Metzger C, et al. 3-Year clinical outcomes with everolimus-eluting bioresorbable coronary scaffolds the ABSORB Ⅲ trial[J]. Journal of the American College of Cardiology, 2017,70(23):2852-2862.

[16] Gogas BD, King SB, Samady H. Bioresorbable polymeric scaffolds for coronary revascularization: Lessons learnt from ABSORB Ⅲ, ABSORB China, and ABSORB Japan[J]. Global Cardiology Science & Practice, 2015,2015(5):62-69.

[17] 陶波,蒋学俊,方钊,等.冠状动脉生物可降解支架的研究现状[J].中国心血管病研究,2016,14(4):289-292.

Tao B, Jiang XJ, Fang Z, et al. The research of biodegradable coronary artery stents[J]. Chinese Journal of Cardiovascular Research,2016,14(4):289-292.

[18] 宋雷,徐波.中国生物可吸收支架的研究与展望[J].中国心血管杂志,2019,24(6): 496-498.

Song L, Xu B. Research status and future perspectives of bioresorbable vascular scaffolds in China[J].Chinese Journal of Cardiovascular Medicine,2019,24(6): 496-498.

[19] 陶凌.NeoVas生物可吸收支架临床研究结果报告[R].西安:曲江国际会议中心,2019.

[20] Han YL, Xu B, Fu GS, et al. A randomized trial comparing the NeoVas sirolimus-eluting bioresorbable scaffold and metallic everolimus-eluting stents[J]. JACC Cardiovascular Interventions, 2018,11(3):260-272.

[21] 365医学网.TCT 2018｜韩雅玲院士解读Neovas 可吸收系列研究结果[EB/OL].（2018-9-26）. http://www.365heart.com/wap1/newwap1/shownews.asp?id=130884.

[22] 齐璐璐,沈雳,吴轶喆.自研生物可吸收支架获批上市[N].健康报,2020-3-16(2).

[23] 沈雳,葛均波.生物可降解支架的研究与展望[J].中华医学信息导报,2016,31(19): 17.

[24] 国家药品监督管理局.生物可吸收冠脉雷帕霉素洗脱支架系统产品获批上市[EB/OL]. （2020-03-05）.https://www.nmpa.gov.cn/directory/web/nmpa/yaowen/ypjgyw/20200305164201151.html.

[25] Wu Y,Shen L,Yin J,et al.Twelve-month angiographic and clinical outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold and a metallic stent in patients with coronary artery disease[J]. International Journal of Cardiology,2019,293:61-66.

[26] 复旦大学附属中山医院.十年磨一剑，XINSORB生物可吸收支架获批上市[EB/OL].（2020-02-12）. http://www.zs-hospital.sh.cn/zsyy/n33/n66/u1ai4875.html.

[27] Song L, Sun ZW, Guan CD, et al. First-in-man study of a thinner-strut sirolimus-eluting bioresorbable scaffold (FUTURE-I): Three-year clinical and imaging outcomes[J]. Catheterization and Cardiovascular Interventions,2020, 95(1):648-657.

[28] Xu B. Firesorb PLLA-based sirolimus-eluting scaffold. transcatheter cardiovasc therapeutics[M]. Washington, DC. USA,2016-10-31.

[29] Xu B, Guan CD, Gao RL. A first-in-man study of the firesorb sirolimus target eluting bioresorbable vascular scaffold in patients with coronary artery disease(FUTURE-Ⅰ):Two-year clinical and imaging outcomes[J]. Chinese Circulation Journal,2018,33(S1):137.

[30] Song L, Sun ZW, Guan CD, et al. First-in-man study of a thinner-strut sirolimus-eluting bioresorbable scaffold (FUTURE-I): Three-year clinical and imaging outcomes[J].Catheterization and Cardiovascular Interventions,2020,95(Suppl 1):648-657.

[31] 高润霖,张澍,王增武,等.新中国成立七十年来我国心血管病学的发展[J].中国循环杂志,2019,34(9): 833-843.

Gao RL, Zhang S, Wang ZW, et al. The development of cardiology in China in 70 years since the founding of the people's republic of China[J].Chinese Circulation Journal,2019,34(9): 833-843.

[32] Zheng JF,Qiu H,Tian Y, et al. Preclinical evaluation of a novel sirolimus-eluting iron bioresorbable coronary scaffold in porcine coronary artery at 6 months[J]. JACC Cardiovascular Interventions, 2019: 12 (3):245-255.

[33] 窦克非.铁基生物可吸收支架的特点和研究进展[R].美国圣迭戈:圣迭戈会议中心,2018.

[34] Wu YJ, Sun ZW, Gao LJ, et al. A first-in-man study of the bioheart sirolimus-eluting bioresorbable vascular scaffold in patients with coronary artery disease: Six-month clinical and imaging outcomes[J]. Journal of the American College of Cardiology, 2017,70(18) SB:B7.

[35] Guan CD, Gao LJ, Sun ZW, et al. A first-in-man study of the bioheart sirolimus-eluting bioresorbable scaffold in patients with coronary artery disease: One-year clinical and imaging outcomes[J]. Journal of the American College of Cardiology, 2018, 72(13)SB:B158-B159.

[36] Ferdous M, Wu YJ, Guan CD, et al. A first-in-man study of the bioheart sirolimus-eluting bioresorbable scaffold in patients with coronary artery disease: 2-year clinical and imaging outcomes[J]. Journal of the American College of Cardiology, 2019,74(13) :B174.

[37] 沈莹冉,周永新.生物可降解冠状动脉支架的研究进展[J].外科研究与新技术,2014,3(4):267-274.

Shen YR, Zhou YX. Progess of biodegradable coronary stents[J].Surgical Research and New Technique,2014,3(4):267-274.

服务与反馈：

【文章下载】【加入收藏】

提示：您还未登录，请登录！点此登录